Business Wire

Helperby Therapeutics announces phase 1 results demonstrating multiple benefits of its unique combination antibiotic therapy - effective against the WHO Critical Priority Carbapenem resistant bacterial pathogens

Jaa

Helperby Therapeutics Ltd (Helperby) has presented data at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) announcing Phase I results on the tolerability, pharmacokinetics, pharmacodynamics and efficacy of AZT and colistin both alone and as a combined therapy, against multi-drug resistant Enterobacteriaceae (CRE), one of the most serious drug resistant pathogens.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180419005128/en/

Helperby also presented preclinical data which shows that AZT is active against carbapenem and colistin resistant Enterobacteriaceae. AZT is a DNA chain terminator and represents a new class of antibacterial agent against the most resistant Gram-negative bacteria. Further data were presented showing the combination to be active in animal models.

This research paves the way for further clinical trials and the potential for the development of a new class of antibiotics, effective against some of the most resistant pathogens. This combination could reach the market in just three to five years.

The significance of these data is that the WHO Critical Priority Gram-negative Carbapenem Resistant bacterial pathogens will contribute to the 10 million deaths which are predicted worldwide by 2050 from treatment-resistant infectionsi. The increasing resistance of pathogens to antibiotics is a serious threat to modern medicine. Blood-stream infections with these highly resistant bacteria can result in fatality rates of over 50%ii.

The combination provides antibiotic enhancement with a low dose of colistin, which is safe and tolerable in humans as demonstrated by the phase 1 results, and so avoids the risk of renal toxicity associated with colistin in higher doses.

Helperby’s new class of ARB antibiotic therapy is one of only a handful of drug candidates that the World Health Organisationiii has identified as in development to tackle the three WHO Critical Priority pathogens; Carbapenem-resistant Enterobacteriaceae (CRE), carbapenem-resistant Acinetobacter (CRAB) and carbapenem-resistant pseudomonas aeruginosa(CRPA).

AZT and colistin are known entities and their mode of action, side-effects and interactions are well known by regulatory authorities.

“Our unique approach of combining antimicrobial resistance breakers such as azidothymidine with existing antibiotics has the potential to reach the market with a new class of effective antibiotic therapy in 3 to 5 years”, said Professor Coates, founder and Chief Scientific Officer at Helperby Therapeutics.

“Helperby has developed a strong candidate for a longer lasting therapy effective against multiple drug- resistant infections,” says CEO Dennis Molnar. “It’s well established that combination therapies prevent the emergence of resistance, and Helperby’s combination technique has the potential to extend the life of last-resort antibiotics which are under huge threat from the accelerating emergence of antimicrobial resistance.”

Press pack at www.helperby.com

i de Kraker, M. E., Stewardson, A. J., & Harbarth, S. (2016). Will 10 million people die a year due to antimicrobial resistance by 2050?. PLoS medicine, 13(11), e1002184.

ii Sexton, M. E., Bower, C., Sukumaran, S., & Jacob, J. T. (2017, October). Comparison of 30-and 90-Day Mortality Rates in Patients with Cultures Positive for Carbapenem-resistant Enterobacteriaceae and Acinetobacter in Atlanta, 2011–2015. In Open forum infectious diseases (Vol. 4, No. suppl_1, pp. S44-S44). US: Oxford University Press.

iii Antibacterial agents in clinical development: an analysis of the antibacterial clinical development pipeline, including tuberculosis. Geneva: World Health Organization; 2017 (WHO/EMP/IAU/2017.11). Licence: CC BY-NC-SA 3.0 IGO.

Contact information

Helperby Therapeutics
Beth Lowes
beth@roadcommunications.co.uk
+44(0)2089955832

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Pacific Drilling Announces Second-Quarter 2018 Results15.8.2018 00:38Tiedote

Pacific Drilling S.A. (OTC: PACDQ) today reported results for the second quarter of 2018. Net loss for the second-quarter 2018 was $103.7 million or $4.86 per diluted share, compared to net loss of $96.1 million or $4.50 per diluted share for the first-quarter 2018, and net loss of $138.1 million or $6.48 per diluted share for second-quarter 2017. Pacific Drilling CEO Paul Reese commented, “This quarter we continued to provide outstanding operational services to our clients, delivering revenue efficiency of 98.7 percent. Our strong operating results have been recognized by clients as we successfully secure new work for our high-specification, deepwater drillship fleet. Petronas recently exercised its option to contract Pacific Santa Ana for an additional year of work commencing in mid-2019. In addition, we have a letter of intent from Eni for Pacific Bora to work in Nigeria, as well as two letters of award for drilling services in the U.S. Gulf of Mexico for Pacific Khamsin and Pacific

Gilead Sciences Announces Executive Promotions15.8.2018 00:00Tiedote

Gilead Sciences, Inc. (NASDAQ: GILD) today announced that Gregg Alton has been appointed Chief Patient Officer, a newly created role that will facilitate access to the company’s medicines and increase focus on reaching patients. The company also announced that Diana Brainard, MD, has been promoted to Senior Vice President, HIV and Emerging Viral Infections, and that Andrew Cheng, MD, PhD, Chief Medical Officer, has decided to leave Gilead to pursue another opportunity. Mr. Alton joined the company nearly 20 years ago and was the architect of its access program, which has enabled Gilead’s HIV medicines to reach more than 11 million people in the developing world. He has helped shape the organization in a number of executive positions, including as general counsel, and more recently, leading the company’s international commercial operations and corporate affairs groups. Prior to joining Gilead, he was an attorney at the law firm of Cooley Godward, LLP, where he specialized in mergers and

Thales and Gemalto Announce Regulatory Clearance from the Minister of Innovation in Canada14.8.2018 19:00Tiedote

Regulatory News: Reference is made to the joint press release by Thales (Euronext Paris: HO) and Gemalto (Euronext Amsterdam and Paris: GTO) dated 27 March 2018 in relation to the launch of the recommended all-cash offer by Thales for all the issued and outstanding shares of Gemalto (the “Offer”), the publication of the Offer Document, and the joint press release of Thales and Gemalto dated 10 August 2018 in relation to the further extension of the Acceptance Period. Terms not defined in this press release will have the meaning as set forth in the Offer Document. Thales and Gemalto today announce that they have received foreign investment Regulatory Clearance in Canada. Together with the anti-trust clearance obtained in China and Israel, and clearance relating to foreign investments in Australia, Thales and Gemalto have obtained 4 of the required 14 Regulatory Clearances. Thales and Gemalto continue to work constructively with the competent antitrust authorities to obtain the remaining

BCW Acquires Creative Powerhouse HZ, Significantly Expanding Expertise in Integrated Communications14.8.2018 17:26Tiedote

BCW (Burson Cohn & Wolfe), a leading global communications agency and a WPP company, today announced it has acquired HZ, one of the largest independent, digitally driven, integrated creative agencies in the U.S. Headquartered in Rockville, Maryland with offices in Baltimore, Los Angeles, New York and Washington, D.C., the acquisition will add the capability of HZ’s nearly 200 creative and digital professionals to BCW’s deep expertise in integrated communications across all industry sectors. HZ’s wide-ranging offerings include a full spectrum of multichannel digital design and development, mobile activation, social media, brand and identity creation, content, film and video production, search marketing (SEO/SEM), data and analytics as well as integrated media solutions. HZ’s broad client base spans the consumer, hospitality, food & beverage, education, B2B, real estate, sports & entertainment, healthcare and technology industries and counts Hilton Worldwide, Salesforce.org and Tishman S

Andersen Global Initiates Expansion in Mozambique14.8.2018 16:30Tiedote

Andersen Global continues expansion in Africa with Isalcio Mahanjane e Associados, a law firm headquartered in Maputo, Mozambique. The collaboration with Isalcio Mahanjane e Associados signifies Andersen’s growth in the African region, as Mozambique provides strategic coverage in Southeast Africa and is the sixth country to collaborate or join in Africa in the past 14 months. Led by Managing Partner Isalcio Mahanjane, the firm includes 10 professionals and specializes in providing quality services in all branches of law for corporations and individuals. These services include commercial and corporate law, banking and financial law, labor law, real estate management, oil and gas, mines, and law and administrative litigation. “Mozambique will be a key point of connectivity with our practice in Portugal as we continue to focus on best-in-class solutions in Africa,” commented Global Chairman and Andersen Tax LLC CEO, Mark Vorsatz. “Isalcio and his team are passionate about their practice a

CTS Engines Inducts First PW2000 Engine14.8.2018 15:00Tiedote

CTS Engines, the global leader for mature engine maintenance within the Aerospace & Defense industry, announced today that it had inducted the first PW2000 engine into its engine overhaul facility in Ft. Lauderdale, FL. Along with the CF6-80C2, CF6-80A, and CF6-50C2, the PW2000 represents the fourth engine model type serviced by CTS. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180814005021/en/ PW2000 Engine. (Photo: Business Wire) “The profile of the PW2000 engine—which will continue to operate on B757s in cargo configuration and on C-17 Globemaster military transport aircraft for years to come—is an ideal fit for the CTS product line,” said Vesa Paukkeri, CTS’s President and Chief Operating Officer. “CTS is the go-to independent jet engine MRO for sunset engines operating in cargo and military transport configurations. We look forward to servicing this engine through the remainder of its time on wing over the next 30+ ye

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme